EQL PHARMA AB (7JK) - Net Assets
Based on the latest financial reports, EQL PHARMA AB (7JK) has net assets worth €269.78 Million EUR (≈ $315.40 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€813.54 Million ≈ $951.11 Million USD) and total liabilities (€543.76 Million ≈ $635.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read 7JK total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €269.78 Million |
| % of Total Assets | 33.16% |
| Annual Growth Rate | 21.37% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.69 |
EQL PHARMA AB - Net Assets Trend (2022–2025)
This chart illustrates how EQL PHARMA AB's net assets have evolved over time, based on quarterly financial data. Also explore EQL PHARMA AB total assets for the complete picture of this company's asset base.
Annual Net Assets for EQL PHARMA AB (2022–2025)
The table below shows the annual net assets of EQL PHARMA AB from 2022 to 2025. For live valuation and market cap data, see EQL PHARMA AB (7JK) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €221.03 Million ≈ $258.41 Million |
+24.37% |
| 2024-03-31 | €177.73 Million ≈ $207.78 Million |
+14.85% |
| 2023-03-31 | €154.75 Million ≈ $180.92 Million |
+25.18% |
| 2022-03-31 | €123.63 Million ≈ $144.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to EQL PHARMA AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 174.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €152.08 Million | 68.81% |
| Other Components | €68.95 Million | 31.19% |
| Total Equity | €221.03 Million | 100.00% |
EQL PHARMA AB Competitors by Market Cap
The table below lists competitors of EQL PHARMA AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HomesToLife Ltd
NASDAQ:HTLM
|
$148.88 Million |
|
United Paper Public Company Limited
BK:UTP
|
$148.91 Million |
|
KJTS
KLSE:0293
|
$149.05 Million |
|
NanoenTekInc
KQ:039860
|
$149.06 Million |
|
KB Star REIT Co. Ltd.
KO:432320
|
$148.79 Million |
|
Formuepleje Limittellus
CO:FPILIM
|
$148.75 Million |
|
Silver X Mining Corp
V:AGX
|
$148.73 Million |
|
Theratechnologies Inc.
TO:TH
|
$148.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EQL PHARMA AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 177,727,000 to 221,034,000, a change of 43,307,000 (24.4%).
- Net income of 43,123,000 contributed positively to equity growth.
- New share issuances of 194,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €43.12 Million | +19.51% |
| Share Issuances | €194.00K | +0.09% |
| Other Changes | €-10.00K | -0.0% |
| Total Change | €- | 24.37% |
Book Value vs Market Value Analysis
This analysis compares EQL PHARMA AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.60x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.06x to 0.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | €4.25 | €4.53 | x |
| 2023-03-31 | €5.32 | €4.53 | x |
| 2024-03-31 | €6.12 | €4.53 | x |
| 2025-03-31 | €7.61 | €4.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EQL PHARMA AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.51%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.55%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 3.66x
- Recent ROE (19.51%) is above the historical average (19.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 25.52% | 7.70% | 1.72x | 1.92x | €19.19 Million |
| 2023 | 19.98% | 11.90% | 0.91x | 1.85x | €15.45 Million |
| 2024 | 12.78% | 8.59% | 0.71x | 2.10x | €4.93 Million |
| 2025 | 19.51% | 11.55% | 0.46x | 3.66x | €21.02 Million |
Industry Comparison
This section compares EQL PHARMA AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $847,973,267
- Average return on equity (ROE) among peers: -93.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EQL PHARMA AB (7JK) | €269.78 Million | 25.52% | 2.02x | $148.83 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.51 Billion | 11.81% | 0.39x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| Alkermes plc (8AK) | $1.07 Billion | 1.94% | 0.48x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $9.58 Million | -63.03% | 0.52x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $3.54 Million | -57.78% | 0.18x | $1.75 Million |
| Apontis Pharma AG (APPH) | $40.71 Million | -1.83% | 0.33x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.